BioSpace News Archive

60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced that its subsidiary, 60P Australia Pty Ltd, will not re-submit its investigational new drug application (“IND”) for ACLR8-LR, a Phase IIB study of tafenoquine compared to placebo in patients with mild to moderate COVID-19 disease and low risk of disease progression.

Invitae, a leading medical genetics company, announced results of its collaborative study on universal hereditary cancer genetic testing in all patients with breast cancer in a rural population in the Annals of Surgical Oncology.

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2023 financial results and guidance will be released on Tuesday, November 7, 2023 after the market closes.

Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), today announced preliminary financial results for the third quarter ended Sept. 30, 2023, and provided updated financial guidance for 2023.

CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release third quarter 2023 financial and operating results after market close on Thursday, October 26th, 2023.

Tevogen Bio Inc. congratulates Professor Sten Vermund, MD, PhD, Chairperson of Tevogen Bio’s Innovation and Public Health Advisory Board, on being elected to serve as the President of the Global Virus Network.

Ultragenyx Pharmaceutical Inc. reported the grant of 80,366 restricted stock units of the company’s common stock and the grant of non-qualified stock options to purchase an aggregate of 140,469 shares of common stock of the company to Howard Horn, its newly appointed Chief Financial Officer and Executive Vice President, Corporate Strategy.

Ascentage Pharma announced that the Center for Drug Evaluation of China NMPA has approved a global pivotal registrational Phase III study designed to evaluate a key drug candidate in Ascentage Pharma’s pipeline, Bcl-2 inhibitor APG-2575, in combination with the Bruton’s tyrosine kinase inhibitor acalabrutinib.

Anbio Biotechnology (“Anbio”), a leading provider of innovative diagnostic solutions, successfully showcased its debut at AACC Middle East 2023 held in Dubai from October 7-8, 2023.

Global market leader in molded glass packaging solutions for the pharmaceutical industry, SGD Pharma announces the latest expansion of its Sterinity range of Ready-To-Use (RTU) Type I molded glass vials.